EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial ( TERA305 Study)

Jun Sung Moon iD, Kyung Ah Han iD, Dong-Lim Kim, Sang Yong Kim, Soo-Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh iD, Ji A Seo, Sang-Ah Chang, Moon-Kyu Lee, Kyu Jeung Ahn und 3 weitere

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11955-11965

DOI: 10.1111/dom.71315 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 05.10.2026. Verfasst von Jun Sung Moon und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin, Benzhydryl Compounds, Glucosides. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Handok Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg ( n = 107) or placebo ( n = 107) once daily for 24 weeks, in addition to metformin (≥ 1000 mg/day) and empagliflozin (25 mg/day). In a subsequent 28‐week open‐label extension, all patients received teneligliptin 20 mg/day. The primary endpoint was HbA1c change from baseline to week 24.

Results

At week 24, the least squares mean (LSM) change in HbA1c from baseline was −0.70% ± 0.06% in the teneligliptin group and −0.03% ± 0.06% in the placebo group, with a placebo‐adjusted LSM change of −0.67% (95% CI, −0.84 to −0.49; p < 0.0001), demonstrating the superiority of teneligliptin. A significant between‐group difference was already evident at week 4 (placebo‐adjusted LSM change, −0.36%; p < 0.0001). Significant reductions in fasting plasma glucose and glycated albumin and improvement in pancreatic β ‐cell function were observed at week 24. During the open‐label extension, glycaemic improvements were maintained through week 52, although no concurrent randomised control was available beyond week 24. Placebo‐group patients achieved a similar benefit after switching to teneligliptin. Safety outcomes did not differ between groups.

Conclusions

Adding teneligliptin to metformin and empagliflozin in patients with inadequately controlled T2DM significantly improved glycaemic control and β ‐cell function over 24 weeks and was well tolerated through 52 weeks. Trail Registration ClinicalTrials.gov Identifier: NCT05504226.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2MetforminBenzhydryl CompoundsGlucosidesHypoglycemic AgentsPyrazolesThiazolidinesHumansDouble-Blind MethodFemaleMaleMiddle AgedDrug Therapy, CombinationGlycated HemoglobinTreatment OutcomeBlood GlucoseAgedHypoglycemiaAdultDipeptidyl-Peptidase IV Inhibitors

Stichwörter der Autor:innen

Type 2 diabetes mellituscombinationdrug therapyglycated haemoglobinsodium‐glucose transporter 2 inhibitorsteneligliptin

Substanzen

3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidineMetforminBenzhydryl CompoundsGlucosidesHypoglycemic AgentsGlycated HemoglobinPyrazolesempagliflozinThiazolidinesBlood Glucose

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University School of Medicine, Gwangju, Korea.
  • Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
  • Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.

ORCID-Profile: Jun Sung Moon, Kyung Ah Han, Tae Keun Oh, Chul Sik Kim, Bong-Soo Cha

Förderung

  • Handok Pharmaceuticals

Zitieren

APA

Moon, J. S., Han, K. A., Kim, D. L., Kim, S. Y., Kim, S. K., Ku, B. J., Lee, W. J., Oh, T. K., Seo, J. A., Chang, S. A., Lee, M. K., Ahn, K. J., Kim, C. S., Kim, T. N., & Cha, B. S. (2026). A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial ( TERA305 Study). Diabetes, Obesity and Metabolism, 28(12), 11955-11965. https://doi.org/10.1111/dom.71315

Vancouver

Moon JS, Han KA, Kim DL, Kim SY, Kim SK, Ku BJ, et al. A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial ( TERA305 Study). Diabetes, Obesity and Metabolism. 2026;28(12):11955-11965. doi:10.1111/dom.71315

BibTeX
@article{Moon2026,
  author = {Moon, Jun Sung and Han, Kyung Ah and Kim, Dong-Lim and Kim, Sang Yong and Kim, Soo-Kyung and Ku, Bon Jeong and Lee, Woo Je and Oh, Tae Keun and Seo, Ji A and Chang, Sang-Ah and Lee, Moon-Kyu and Ahn, Kyu Jeung and Kim, Chul Sik and Kim, Tae Nyun and Cha, Bong-Soo},
  title = {A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial ( TERA305 Study)},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11955--11965},
  doi = {10.1111/dom.71315}
}
Kostenlos starten →